Holen Sie sich die Stockscreener-App
4.84
5.84%
-0.30
Schlusskurs vom Vortag:
$5.14
Offen:
$5.13
24-Stunden-Volumen:
83,597
Relative Volume:
0.38
Marktkapitalisierung:
$685.78M
Einnahmen:
$31.37M
Nettoeinkommen (Verlust:
$-53.77M
KGV:
-3.3294
EPS:
-1.4537
Netto-Cashflow:
$-49.02M
1W Leistung:
+20.70%
1M Leistung:
+58.69%
6M Leistung:
-30.96%
1J Leistung:
-79.16%
1-Tages-Spanne:
$4.83
$5.1386
1-Wochen-Bereich:
$4.01
$5.20
52-Wochen-Spanne:
$1.97
$23.50
Silence Therapeutics Plc Adr Stock (SLN) Company Profile
Firmenname
Silence Therapeutics Plc Adr
Sektor
Branche
Telefon
44-0-20-3457 6900
Adresse
72 HAMMERSMITH ROAD, LONDON
Vergleichen Sie SLN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLN
Silence Therapeutics Plc Adr
|
4.84 | 189.39M | 31.37M | -53.77M | -49.02M | -1.4537 |
|
ONC
Beigene Ltd Adr
|
238.76 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.03 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2548 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
596.85 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
72.69 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Silence Therapeutics Plc Adr Stock (SLN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-11 | Eingeleitet | Goldman | Sell |
| 2024-12-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2024-09-03 | Eingeleitet | Jefferies | Buy |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Outperform |
Silence Therapeutics Plc Adr Aktie (SLN) Neueste Nachrichten
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade - MSN
Silence Therapeutics stock hits 52-week low at $3.19 By Investing.com - Investing.com South Africa
Silence Therapeutics stock hits 52-week low at $3.19 - Investing.com
Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know - MSN
Silence Therapeutics stock hits 52-week low at $3.66 amid downturn - Investing.com
Silence Therapeutics stock hits 52-week low at $3.66 amid downturn By Investing.com - Investing.com South Africa
Taiwan Semiconductor Valuation: How Realistic Is the Price? - The Globe and Mail
Silence Therapeutics stock hits 52-week low at $4.04 amid challenges - Investing.com
Silence Therapeutics stock hits 52-week low at $4.04 amid challenges By Investing.com - Investing.com South Africa
Earnings call transcript: Silence Therapeutics sees stock rise post-earnings - Investing.com
BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment - GlobeNewswire Inc.
Goldman Sachs cuts Silence Therapeutics stock rating to Sell By Investing.com - Investing.com South Africa
Should investors be concerned about Silence Therapeutics Plc ADR (SLN)? - US Post News
Akoya Biosciences Inc (AKYA)’s Day in Review: Closing at 2.34, Down by -4.88 - The Dwinnex
Cloudflare Inc’s (NET) Stock: A 29.10% Simple Moving Average for the Past 20 Days - The News Heater
Silence Therapeutics's SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Silence Therapeutics's SWOT analysis: stock poised for growth amid challenges - Investing.com
H.C. WAINWRIGHT MAINTAINS $75 TARGET ON SILENCE THERAPEUTICS STOCK By Investing.com - Investing.com South Africa
European Equities Traded in US as American Depositary Receipts Surge on Monday - MSN
Top 3 Health Care Stocks That May Explode In Q4 - Benzinga
Silence Therapeutics' SWOT analysis: stock's potential in RNAi therapeutics - Investing.com
Silence Therapeutics' SWOT analysis: RNAi stock poised for growth amid clinical progress - Investing.com India
Silence Therapeutics announces additional results from SANRECO study - TipRanks
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels - MSN
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com
United States shares mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com India
Silence Therapeutics weakness after AHA updates ‘overdone,’ says BMO Capital - TipRanks
SILENCE THERAPEUTICS PLC SPONSORED ADR trading resumes - TipRanks
Top 3 Health Care Stocks You'll Regret Missing In Q4 - Benzinga
Silence Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Silence Therapeutics: Rising Assets Amid Growing Losses - TipRanks
Biogen's Lupus Candidate Meets Key Goals in Phase III Study - Yahoo Finance
The 3 Best Gene Editing Stocks to Buy in August 2024 - Markets Insider
Zerlasiran shows promise in phase 2 study for cardiovascular risk - Investing.com India
Recursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains? - Yahoo Finance
Here's Why Momentum in Silence Therapeutics PLC Sponsored ADR (SLN) Should Keep going - MSN
symbol__ Stock Quote Price and Forecast - CNN
Claire Keast-Butler - Cooley
Our approach to nucleotide-based therapeutics - AstraZeneca
Silence Therapeutics Plc ADR (SLN-Q) QuotePress Release - The Globe and Mail
5 Stocks to Buy as the Drug Industry Bets Big on Innovation - Nasdaq
Silence Therapeutics PLC Sponsored ADR (SLN) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Genfit (NASDAQ:GNFT) Stock Quotes, Forecast and News Summary - Benzinga
Silence Therapeutics (SLN) - Zacks Investment Research
Finanzdaten der Silence Therapeutics Plc Adr-Aktie (SLN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.60%
6.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):